Blog
Cobolimab Biosimilar HDBS0008: Expanding Access to TIM-3 Immune Checkpoint Inhibition
Cobolimab is an investigational monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), an immune checkpoint receptor implicated in T-cell exhaustion a
…
25th Nov 2024
Atezolizumab Biosimilar HDBS0009: Enhancing Access to PD-L1 Immunotherapy
Atezolizumab (Tecentriq) is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), a key immune checkpoint used by cancer cells to evade immune detection. By inhibiting PD-L1
…
25th Nov 2024